Sunshine Biopharma, Inc.
SBFM
$1.40
-$0.02-1.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -50.09% | 45.33% | -80.18% | -142.32% | 61.50% |
| Total Depreciation and Amortization | 11.88% | -0.92% | 1.24% | 26.92% | 19.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | -- | -100.00% |
| Change in Net Operating Assets | -6.34% | 54.44% | -477.04% | 94.49% | -111.37% |
| Cash from Operations | 25.70% | 49.70% | -150.35% | 70.27% | -43.72% |
| Capital Expenditure | -2,033.33% | 92.69% | 80.15% | 46.95% | -1,449.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -96.91% | 60.71% | -598.53% | -114.20% | 171.36% |
| Cash from Investing | -179.43% | 66.89% | 8.11% | -6.68% | 18.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -239.53% | -119.57% | 395.96% | -3.85% | 3.38% |
| Issuance of Common Stock | 932.54% | -78.04% | -14.63% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 967.79% | -83.54% | 10.08% | 6,624.48% | -100.53% |
| Foreign Exchange rate Adjustments | 3,391.18% | 98.39% | -182.26% | 199.28% | -93.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 239.62% | 38.02% | -460.58% | 111.79% | -619.00% |